Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection | Zendy

Michael Fried | Zendy; Mitchell L. Shiffman | Zendy; K. Rajender Reddy | Zendy; Coleman Smith | Zendy; George Marinos | Zendy; Fernando Lopes Gonçales | Zendy; Dieter Häussinger | Zendy; M. Diago | Zendy; Giampiero Carosi | Zendy; Daniel Dhumeaux | Zendy; Antonio Craxı̀ | Zendy; Amy Lin | Zendy; Joseph H. Hoffman | Zendy; Jian Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Author(s) -

Michael Fried,

Mitchell L. Shiffman,

K. Rajender Reddy,

Coleman Smith,

George Marinos,

Fernando Lopes Gonçales,

Dieter Häussinger,

M. Diago,

Giampiero Carosi,

Daniel Dhumeaux,

Antonio Craxı̀,

Amy Lin,

Joseph H. Hoffman,

Jian Yu

Publication year - 2002

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa020047

Subject(s) - ribavirin , medicine , peginterferon alfa 2a , gastroenterology , interferon alfa , alpha interferon , hepatitis c , hepatitis c virus , placebo , interferon , immunology , virus , pathology , alternative medicine

Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research